Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crisugabalin in Restless Legs Syndrome
NCT07453862Phase 1Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of crisugabalin besilate in restless legs syndrome (RLS), sponsored by Beijing Friendship Hospital. Primary endpoint: International Restless Legs Syndrome Scale at 12 weeks. Started Mar 2026; status: recruiting.
02
Drugs
crisugabalin besilate
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT07453862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07453862.